Daily Anesthesiology Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Three perioperative studies stood out: a 15,550-patient prospective cohort mapped which postoperative complications most drive mortality after cardiac surgery (acute kidney injury dominated); a mechanistic cohort identified a high-risk sepsis endotype via phosphorylated TLR4; and a systematic review/meta-analysis found intravenous lidocaine reduces pain and PONV after thyroidectomy while improving quality of recovery.
Research Themes
- Perioperative risk stratification and complication prevention in cardiac surgery
- Precision endotyping in sepsis for critical care anesthesia
- Optimization of multimodal analgesia with intravenous lidocaine
Selected Articles
1. Association between complications and mortality after cardiac surgery: Results from the VISION Cardiac Surgery prospective cohort study.
In a 15,550-patient international prospective cohort, acute kidney injury had the largest population-attributable fraction for 30-day mortality after cardiac surgery (37%), followed by bleeding, infection, and myocardial injury. Targeted prevention of these complications could meaningfully reduce early and 1-year mortality.
Impact: This large, multicenter prospective study quantitatively ranks complications by their mortality impact, providing clear targets—especially acute kidney injury—for quality improvement and guideline development.
Clinical Implications: Prioritize perioperative AKI prevention bundles (hemodynamic optimization, nephrotoxin avoidance, early detection), strengthen bleeding and infection prevention pathways, and monitor myocardial injury to reduce early mortality after cardiac surgery.
Key Findings
- Among 15,550 cardiac surgery patients, 30-day mortality was 3.0% and 1-year mortality was 5.5%.
- Acute kidney injury occurred in 16.8% and had the largest PAF for 30-day mortality (37%; aHR 4.47).
- Bleeding (PAF 12%), infection (PAF 12%), and myocardial injury after cardiac surgery (PAF 10%) were also major contributors.
Methodological Strengths
- Large multicenter prospective cohort across 24 centers in 12 countries
- Population-attributable fraction analysis to quantify contribution of complications to mortality
Limitations
- Observational design limits causal inference and residual confounding is possible
- Cross-center heterogeneity and definitions may affect generalizability
Future Directions: Test targeted AKI, bleeding, infection, and myocardial injury prevention bundles in pragmatic multicenter trials and evaluate impact on 30-day and 1-year mortality.
OBJECTIVES: The most prognostically important complications after cardiac surgery to target for prevention remain uncertain. We aimed to assess the relationship between postoperative complications and mortality at 30 days and 1 year after cardiac surgery and rank the complications by their contribution to mortality. METHODS: We completed an analysis of 15,550 patients from the Vascular Events in Surgery Patients Cohort Evaluation (VISION) Cardiac Surgery prospective cohort study, which enrolled 15,971 pat
2. Phosphorylated toll-like receptor 4 defines a high-risk sepsis endotype.
Using a validated proximity ligation assay in 100 septic patients, in vivo TLR4 phosphorylation was generally low but elevated in a subset strongly associated with higher 30-day mortality, independent of SOFA score and demographics. These data delineate a high-risk TLR4-activated sepsis endotype and support biomarker-guided precision medicine.
Impact: It provides mechanistic patient stratification that can explain prior trial failures of TLR4 inhibitors and lays a foundation for endotype-enriched interventional studies.
Clinical Implications: Phospho-TLR4 measurement could identify septic patients at high risk who might benefit from TLR4-targeted or intensified therapies, enabling biomarker-enriched clinical trials.
Key Findings
- TLR4 activation (phosphorylation) was quantified in vivo on day 1 and day 4 in 100 septic patients using a proximity ligation assay.
- Overall TLR4 activation was low, but a subset exhibited elevated activation associated with reduced 30-day survival.
- Elevated activation predicted mortality independently of SOFA score, age, sex, and infection focus (multivariable Cox p=0.006).
Methodological Strengths
- Use of a validated proximity ligation assay to quantify receptor phosphorylation in vivo
- Prospective sampling at two time points with multivariable survival analysis
Limitations
- Single-cohort study with modest sample size (n=100) limits generalizability
- Assay availability and standardization may constrain near-term clinical use
Future Directions: Validate the phospho-TLR4 endotype across diverse cohorts and test TLR4-targeted therapies in biomarker-enriched randomized trials.
BACKGROUND: Sepsis is a life-threatening condition characterized by a dysregulated immune response to infection. Toll-like receptor 4 plays a central role in pathogen recognition and inflammatory signalling and has been considered a key driver of sepsis pathophysiology. Pharmacological inhibition of this receptor showed beneficial effects in experimental models but failed in clinical trials. We therefore aimed to quantify in vivo activation of Toll-like receptor 4 in patients with sepsis and to de
3. Efficacy and safety of intravenous lidocaine in thyroidectomy: a systematic review and meta-analysis with trial sequential analysis and meta-regression.
Across 11 RCTs (n=943), perioperative IV lidocaine reduced postoperative pain at several time points (notably at 24 h and 48 h), lowered PONV risk (RR 0.46), and improved quality of recovery on postoperative days 1–2. Heterogeneity was substantial for some pain endpoints, so clinical significance should be interpreted cautiously.
Impact: Synthesizes randomized evidence with modern meta-analytic methods, supporting IV lidocaine as a pragmatic component of multimodal analgesia in thyroidectomy.
Clinical Implications: Consider IV lidocaine infusions as part of ERAS pathways for thyroidectomy to reduce pain and PONV and improve early recovery, while monitoring for heterogeneity in effect and adhering to safety protocols.
Key Findings
- Meta-analysis of 11 RCTs (943 patients) found lower postoperative pain scores at 1, 4, 12, 24, and 48 hours with IV lidocaine.
- PONV incidence was significantly reduced (RR 0.46), and QoR scores improved on postoperative days 1 and 2.
- Heterogeneity was substantial for some pain endpoints (e.g., 24 h pain I² = 88.2%), warranting cautious interpretation of clinical relevance.
Methodological Strengths
- PRISMA-compliant systematic review and inclusion of only RCTs
- Use of HKSJ method under heterogeneity and trial sequential analysis/meta-regression
Limitations
- Between-study heterogeneity for several pain outcomes
- Variable dosing regimens and perioperative protocols across trials
Future Directions: Standardize dosing regimens and ERAS contexts in future RCTs to refine effect estimates and assess safety endpoints and functional recovery.
BACKGROUND: Thyroidectomy is a common surgical procedure associated with postoperative pain and postoperative nausea and vomiting (PONV), which may impair early recovery and quality of recovery (QoR). Intravenous (IV) lidocaine has been proposed as a component of multimodal analgesia; however, its efficacy and safety in patients undergoing thyroidectomy remain uncertain. Therefore, this systematic review and meta-analysis aimed to evaluate the efficacy and safety of perioperative IV lidocaine in